ImmuCell shifts focus to First Defense, pauses Re-Tain investment due to FDA “Incomplete Letter” linked to aseptic-filling contractor. Q4 sales at $7.6M, down 1.6%, full-year 2025 sales at $27.6M, up 4.3%. Plans non-cash impairment of $2.9M and inventory write-down of $600k. Expanding sales team by 50% for $900M market.

Strategic shift to First Defense as focus outlined in conference call. Re-Tain investment paused due to FDA Incomplete Letter. ImmuCell to finish studies in 2026, seek potential partner. Manufacturing assets redeployed to First Defense. $900M scour-protection market targeted for expansion.

ImmuCell reports lyophilization output up >15% in 2025, with similar gains expected in 2026. Unaudited Q4 sales at $7.6M, down 1.6% YoY. Full-year sales at $27.6M, up 4.3%. Potential non-cash impairment of $2.9M and inventory write-down of $600k.

CEO cites increased demand for scour protection driven by rising calf values. Estimates $900M global market. Plans to increase customer engagement for adoption. Manufacturing output rose >15% in 2025, similar gains targeted for 2026. Domestic sales up 8.7% in Q4, international sales down due to order timing.

Management shifts focus to First Defense, pauses Re-Tain investment due to FDA Incomplete Letter. Plans to complete studies in 2026, seek potential partner for Re-Tain. Manufacturing assets to be redeployed to First Defense. $900M scour-protection market targeted for expansion.

ImmuCell evaluates $15M in Re-Tain-related assets for repurposing to First Defense. Expects non-cash impairment of $2.9M and inventory write-down of $600k. Expanding sales team by 50%. Additional capital may be needed for freeze dryer and facility repurposing. Full-year financial results call set for late February. CEO Michael Brigham steps down after 30 years of service.

Read more at Yahoo Finance: ImmuCell Q4 Earnings Call Highlights